Business Context and Reporting Period
Organon & Co. (NYSE: OGN) filed a Form 8-K on July 23, 2026, reporting the results of a special meeting of stockholders held on that date. The meeting addressed proposals related to a merger transaction with Sun Pharmaceutical Holdings USA, Inc. ("Sun Pharma USA").
Key Financial Metrics
This filing is a current report regarding corporate governance and voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes and Voting Results
The filing details the approval of two key proposals by stockholders:
- Proposal 1 (Merger Agreement): Approved to adopt the Merger Agreement dated April 26, 2026. Under the agreement, a wholly-owned subsidiary of Sun Pharma USA will merge with Organon, with Organon surviving as a wholly-owned subsidiary of Sun Pharma USA.
- Proposal 2 (Executive Compensation): Approved on a non-binding, advisory basis the compensation payable to named executive officers related to the Merger.
Voting Statistics:
- Shares Outstanding: 262,609,433
- Shares Represented: 195,675,859 (74.51% of total voting power)
- Proposal 1 Results: 192,776,552 For; 2,573,118 Against; 326,189 Abstaining.
- Proposal 2 Results: 185,141,986 For; 9,553,830 Against; 980,043 Abstaining.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the context of the merger transaction. The primary event reported is the successful shareholder vote to proceed with the acquisition by Sun Pharma USA.
Investor Verification Checklist
- Verify the final closing date of the merger with Sun Pharma USA.
- Confirm the exchange ratio or consideration per share for Organon stockholders as detailed in the Merger Agreement.
- Review the definitive proxy statement filed on June 17, 2026, for full details on executive compensation and merger terms.
- Monitor subsequent filings for regulatory approvals required to consummate the transaction.